Malmartel A, Ghasarossian C
Department of Family Medicine, University of Medicine Paris Descartes-Site Cochin, 24, rue du Faubourg Saint-Jacques, 75014, Paris, France.
Eur J Clin Microbiol Infect Dis. 2016 Mar;35(3):447-51. doi: 10.1007/s10096-015-2560-1. Epub 2016 Jan 6.
General practitioners often have to manage urinary tract infections (UTI) with probabilistic treatments, although bacterial resistances are increasing. Therefore, the French Society of Infectious Diseases published new guidelines in 2014. The aim of this study was to investigate the bacterial epidemiology of UTI in the general population in primary care and analyse risk factors for Escherichia coli resistance to antibiotics. A cross-sectional study was conducted in 12 ambulatory laboratories. Patients over 18 years of age coming for urinalysis were included. Risk factors for UTI were collected using a questionnaire and the laboratory records. Bacteria meeting criteria for UTI were analysed. A positive urinalysis was found in 1119 patients, corresponding to 1125 bacterial isolates. The bacterial species were: E. coli (73 %), Enterococcus spp. (7 %), Klebsiella spp. (6 %), Proteus spp. (4 %), Staphylococcus spp. (3 %) and Pseudomonas spp. (2 %). Regardless of the bacteria, the most common resistance was that to co-trimoxazole: 27 % (95 % confidence interval [CI] = [0.24; 0.30]), followed by ofloxacin resistance: 16 % [0.14; 0.18]. Escherichia coli resistances to co-trimoxazole, ofloxacin, cefixime, nitrofurantoin and fosfomycin were, respectively, 25.5 % [0.23; 0.28], 17 % [0.14; 0.20], 5.6 % [0.04; 0.07], 2.2 % [0.01; 0.03] and 1.2 % [0.005; 0.02]. Independent risk factors for E. coli resistance to ofloxacin were age over 85 years (odds ratio [OR] = 3.08; [1.61; 5.87]) and a history of UTI in the last 6 months (OR = 2.34; [1.54; 3.52]). Our findings support the guidelines recommending fluoroquinolone sparing. The scarcity of E. coli resistance to fosfomycin justifies its use as a first-line treatment in acute cystitis. These results should be reassessed in a few years to identify changes in the bacterial epidemiology of UTI.
尽管细菌耐药性不断增加,但全科医生常常不得不采用概率性治疗方法来处理尿路感染(UTI)。因此,法国传染病学会在2014年发布了新的指南。本研究的目的是调查初级保健中普通人群UTI的细菌流行病学,并分析大肠杆菌对抗生素耐药的危险因素。在12个门诊实验室进行了一项横断面研究。纳入前来进行尿液分析的18岁以上患者。通过问卷和实验室记录收集UTI的危险因素。对符合UTI标准的细菌进行分析。在1119名患者中发现尿液分析呈阳性,对应1125株细菌分离株。细菌种类有:大肠杆菌(73%)、肠球菌属(7%)、克雷伯菌属(6%)、变形杆菌属(4%)、葡萄球菌属(3%)和假单胞菌属(2%)。无论何种细菌,最常见的耐药是对复方新诺明的耐药:27%(95%置信区间[CI]=[0.24;0.30]),其次是对氧氟沙星的耐药:16%[0.14;0.18]。大肠杆菌对复方新诺明、氧氟沙星、头孢克肟、呋喃妥因和磷霉素的耐药率分别为25.5%[0.23;0.28]、17%[0.14;0.20]、5.6%[0.04;0.07]、2.2%[0.01;0.03]和1.2%[0.005;0.02]。大肠杆菌对氧氟沙星耐药的独立危险因素是年龄超过85岁(比值比[OR]=3.08;[1.61;5.87])和过去6个月内有UTI病史(OR=2.34;[1.54;3.52])。我们的研究结果支持推荐慎用氟喹诺酮类药物的指南。大肠杆菌对磷霉素耐药性较低,证明其可作为急性膀胱炎的一线治疗药物。这些结果应在几年后重新评估,以确定UTI细菌流行病学的变化。